According to World Health Organization data, approximately 70% of women with polycystic ovary syndrome remain undiagnosed, often enduring 2-3 years of symptoms before receiving proper clinical recognition. This diagnostic gap represents a significant public health challenge, contributing to delayed treatment initiation and prolonged patient suffering.
The recent official renaming from PCOS to polycystic ovary metabolic syndrome (PMOS) directly addresses this crisis by emphasizing the condition’s metabolic components—including insulin resistance and cardiovascular dysfunction—beyond reproductive manifestations. By broadening clinical awareness and encouraging metabolic assessment, the new nomenclature aims to facilitate earlier identification and intervention.
Experts anticipate that the terminology shift will prompt healthcare providers across specialties to maintain heightened diagnostic vigilance, particularly among populations presenting with metabolic dysfunction, irregular menstruation, or unexplained infertility. This enhanced awareness may substantially reduce diagnostic delays and improve clinical outcomes.
Read the full article on GMJ Newsroom.
Was this article helpful?
